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OPTIMIZATION OF TISSUE SAMPLES FOR THE DEVELOPMENT AND 
VALIDATION OF DISEASE BIOMARKERS: THE OPTIMARK PROJECT
INTRODUCTION
The development of new disease
biomarkers is essential for the progress of
personalized medicine. This clinical
approach, allows a great number of
patients to access more efficient and safer
therapeutic protocols, based on molecular
findings in tissue samples obtained from
patients for diagnostic or therapeutic
purposes.
Biobanks, as repositories of human
biological samples, have the responsibility
to provide researchers with samples of
known quality and an estimated potential
for the analysis of DNA, RNA, proteins and
antigenicity. A key element in this context is
the knowledge, control and registration of
all pre-analytical factors related to the final
analytical performance of samples.
This issue is particularly complex when
dealing with samples from a wide range of
tissues, obtained through various
procedures (biopsy, resection or post-
mortem) and potentially tested with
different analytical procedures.
ALGORITHMS PROPOSED TO TEST QUALITY
INSTITUTIONS
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colon, lung, l iver, mama
fatty, fibrous, pancreatic, neuronal
4ºC (post-mortem)
Room temperature 18-28ºC (post-mortem)
37ºC (alive)
Unknown
Autopsy < 6 h post-mortem A06 A06
Autopsy 6-12 h post-mortem A12 A12
Autopsy 12-24 h post-mortem A24 A24
Autopsy 24-48 h post-mortem A48 A48
Autopsy 48-72 h post-mortem A72 A72
Biopsy in culture media BCM BCM
Biopsy BPS BPS
Biopsy in normal saline or phosphate buffered saline BSL BSL
Biopsy in tissue low temperature transport media BTM BTM
Punction PUN PUN
Surgical excision in culture media SCM SCM
Surgical excision SRG SRG
Surgical excision in normal saline or phosphate buffered saline SSL SSL
Surgical excision in tissue low temperature transport media STM STM
Surgical excision in vacuum container VAC VAC
Swab SWB SWB
< 2 min A A
2 to 10 min B B
10 to 20 min C C
20 to 30 min D D
30 to 60 min E E
>60 min F F
Unknown X X
Not applicable (e.g. biopsy, postmorten) N N
< 2 min A A
2 to 10 min B B
10 to 20 min C C
20 to 30 min D D
30 to 60 min E E
>60 min F F
Unknown X X
Not applicable N N
Non-aldehyde with acetic acid ACA ACA
Aldehyde-based ALD ALD
Allprotect ® tissue reagent ALL ALL
Alcohol-based ETH ETH
Non-buffered formalin FOR FOR
Heat stabilization HST HST
Snap freezing SNP SNP
Non-aldehyde based without acetic acid NAA NAA
Neutral buffered formalin NBF NBF
Optimum cutting temperature medium OCT OCT
PAXgene® tissue PXT PXT
RNA Later® RNL RNL
<15 min A (ALL) A (NBF) A (PTX) A (RNL) A (NBF) A (PTX)
15 min to 1 h B (ALL) B (NBF) B (PTX) B (RNL) B (NBF) B (PTX)
1 to 4 h C (ALL) C (NBF) C (PTX) C (RNL) C (NBF) C (PTX)
4 to 8 h D (ALL) D (NBF) D (PTX) D (RNL) D (NBF) D (PTX)
8 to 24 h E (ALL) E (NBF) E (PTX) E (RNL) E (NBF) E (PTX)
24 to 48 h F (ALL) F (NBF) F (PTX) F (RNL) F (NBF) F (PTX)
48 to 72 h G (ALL) G (NBF) G (PTX) G (RNL) G (NBF) G (PTX)
Not applicable (OCT/Snap Frozen) N N N N N N
Unknown X X X X X X
Other Z Z Z Z Z (NBF; brain) Z
PP tube 0.5- to 2-mL** (-85) to (-60) °C A A
PP tube 0.5- to 2-mL (-35) to (-18) °C B B
PP tube 0.5- to 2-mL <-135 ° C V V
Cryotube 1- to 2-mL Liquid nitrogen*** C C
Cryotube 1- to 2-mL (-85) to (-60) °C D D
Cryotube 1- to 2-mL Programmable freezing to <-135 °C E E
PP tube ≥ 5 mL (-85) to (-60) °C J J
PP tube ≥ 5 mL (-35) to (-18) °C K K
Cryotube 1- to 2-mL LN*** after temporary (-85) to (-60) °C N N
Paraffin block RT or 2 to 10°C P P
Bag LN*** G G
PP tube 40 to 500μL (-85) to (-60) °C S S
PP tube 40 to 500μL (-35) to (-18) °C T T
PP tube 40- to 500-μL <-135 ° C W W
Original primary container (-35)-(-18) °C or (-85)-(-60) °C Y Y
Unknown X X
Neutral buffered formalin (ex. Brain) Z Z
Other (ex.Cryomold) Z Z
< 5 years (NBF)
5 - 10 years (NBF)
10 - 20 years (NBF)











































































WITH antigen retrieval :













- But it could have known 
sensitivity of the antibody 
to pre-analytical  factors










EXPECTED IMPACT OF PRE-ANALYTICAL FACTORS ON TISSUE QUALITY
Figure 1. Expected impact by colours of selected SPREC v.2.0 (gray cell) and BRISQ (blue cell) preanalytical factors on tissue quality, over the nucleic acids and antigenicity. Green: optimal
quality or not effect; yellow: moderate quality or unknown effect; red: sub optimal quality.
The purpose of the project, that is currently
being carried out by 17 centres of the
Spanish Network of Biobanks, is to select
and validate the essential preanalytical
variables relevant in analytical testing and
high predictive value for the applicability of
research samples of new tissue biomarkers.
The project will allow a retrospective
analysis of the potential of tissue samples
stored in the Network, and the
effectiveness of the current codification
systems that include pre-analytical
variables. Additionally, the project aims at
developing optimized protocols for
obtaining samples of various tissue origins,
controlling key pre-analytical factors (Fig. 1),
and the evaluation (algorithms) of analytes
(generic and specific) related to biomarkers
(Fig. 2).
In the first phase, 374 patients between 30
and 65 years (in the case of brain samples
up to 75 years without vascular pathology)
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have been selected to test their tissue
samples in order to evaluate long term
storage based on RNA and antigenicity
quality. A representative number of frozen
and formalin-fixed paraffin-embedded
tissue samples stored less than 1 year, 1-5
years, 5-10 years and more than 20 years
have been selected from colon (n=104),
brain (57), lung (76), breast (85), stomach
(17) and endometrium (35).
Correlations will help to analyse the impact
of other key preanalytical factors.
Figure 2. Procedures to evaluate tissue quality, in order to classify the suitability of the sample for the expected application. Green: optimal quality; yellow: moderate quality; red: sub optimal quality.
1. The SPREC coding system and a subset of
BRISQ variables have been used to estimate
the expected quality for each analyte group
(Fig. 1).
2. The Research Group has addressed
strategies independently, and a decision
tree has been developed to assess the
quality of each analyte group (Fig. 2).
PROPOSALS AND CONCLUSIONS
3. Selected retrospective samples are being
analysed in order to validate the proposed
procedure, to evaluate the effect of several
preanalytical factors, as well as the cost-
efectiveness in tissue biomarkers research.
4. A prospective tissue sampling phase shall
be required to validate the gaps on
available information.
